Resultados: 3

J. bras. econ. saúde (Impr.); 15 (1), 2023

Patients with rare diseases frequently face unmet medical needs due to the high costs, lengthy development times, and slow approval processes for new treatments. This case study discusses innovative access alternatives for rare diseases in Brazil, focusing on early access to pabinafusp-alfa for mucopolys...

Texto completo

J. bras. econ. saúde (Impr.); 11 (3), 2019

Objective: To reflect about current pain management in cancer patients treated under the Brazilian Private Healthcare System, considering legal boundaries, access to essential drugs and involved ethical issues. Panelists aimed to reach a consensus about recommendations to increase access to proper analge...

Texto completo (link principal)     Texto completo (link alternativo)    

J. bras. econ. saúde (Impr.); 10 (3), 2018

Objective: Comparing the costs and effectiveness of plasma genotyping versus tumor genotyping for detecting the T790M mutation in advanced non-small cell lung cancer (NSCLC) with a mutation in the epidermal growth factor receptor (EGFR) and that progressed after use of an EGFR tyrosine kinase inhibitor (...

Texto completo (link principal)     Texto completo (link alternativo)